BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37803368)

  • 41. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.
    Braido F; Corsico AG; Paleari D; Piraino A; Cavalieri L; Scichilone N
    Ther Adv Respir Dis; 2022; 16():17534666211066063. PubMed ID: 35044875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
    Luo Z; Lucci G; Santoro L; Topole E; Mariotti F
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102129. PubMed ID: 35525480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
    Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
    Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
    Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beclometasone for chronic obstructive pulmonary disease.
    De Coster DA; Jones M; Thakrar N
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009769. PubMed ID: 24105424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
    Gong Y; Sui Z; Lv Y; Zheng Q; Li L
    Eur J Clin Pharmacol; 2023 Oct; 79(10):1321-1332. PubMed ID: 37507595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review.
    Ritondo BL; Puxeddu E; Calzetta L; Cazzola M; Rogliani P
    Expert Opin Pharmacother; 2021 Apr; 22(5):611-620. PubMed ID: 33131340
    [No Abstract]   [Full Text] [Related]  

  • 50. Evolving to a single inhaler extrafine LABA/LAMA/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE).
    Brusselle G; Himpe U; Fievez P; Leys M; Perez Bogerd S; Peché R; Vanderhelst E; Lins M; Capiau P;
    Respir Med; 2023 Nov; 218():107368. PubMed ID: 37562659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study - The TRIBUNE study".
    Porpodis K; Bartziokas K; Chatziapostolou P; Korkontzelou A; Katerelos P; Efstathopoulos P; Bakakos P
    Respir Med; 2023 Jun; 212():107219. PubMed ID: 36965590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 60. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
    Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
    Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.